Business

Biotech

Next up for KRAS-blocking cancer drug fans: a hugely important data reveal from Mirati Therapeutics

By Adam Feuerstein

Intermountain Medical Center main campus

Business

Intermountain, Amgen subsidiary to launch DNA study of 500,000 patients

By Andrew Joseph

Biotech

Fast-growing Vericel finds success on two fronts: knee surgery and burn care

By Jonathan Saltzman — Boston Globe

Pharmalot

Pharmalittle: Jacobus price for rare disease drug sets up battle with rival Catalyst; Repatha called cost-effective

By Elizabeth Cooney

Biotech

Cymabay’s NASH drug ambitions dealt serious setback with negative study results

By Adam Feuerstein

Business

Sarepta CEO welcomes Vertex’s effort to develop a competing muscular dystrophy drug

By Jonathan Saltzman — Boston Globe

Biotech

Third Rock raises $770 million in new funding round

By Jonathan Saltzman — Boston Globe

Business

Haven wants to help ‘the American public get better health and reduce the costs,’ JPMorgan CEO says

By Kate Sheridan

Biotech

Europe approves first gene therapy to treat rare blood disease

By Damian Garde

Biotech

Amgen’s drug — targeting an ‘undruggable’ cancer protein — shrank tumors in half of patients

By Adam Feuerstein

Pharma

Forget controversy. AstraZeneca’s dynamic duo wants to dominate the market for cancer drugs

By Matthew Herper

Business

Troubled microbiome startup uBiome to lay off some employees, refund payments from federal insurers

By Rebecca Robbins

Biotech

Epizyme seeks early approval for drug to treat ultra-rare tumors

By Jonathan Saltzman — Boston Globe

Health Tech

5 names to know at Facebook: the people behind its push into health care

By Rebecca Robbins and Megan Thielking

Biotech

Biomarin to seek approval for hemophilia gene therapy, but durability questions persist

By Adam Feuerstein and Matthew Herper

Biotech

Novartis CEO coy about pricing its gene therapy for spinal muscular atrophy

By Jonathan Saltzman — Boston Globe

Health Tech

Singapore digital health startup raises $35 million, plans headquarters move to Boston

By Larry Edelman — Boston Globe

Biotech

MIT-owned lab buildings in Kendall Square change hands for reported $1.1 billion

By Tim Logan

Business

Departure of top Haven executive creates void at a crucial stage

By Casey Ross and Kate Sheridan

Pharmalot

Up and down the ladder: the latest comings and goings

By Ed Silverman

Biotech

As more dogs are tested for potential genetic diseases, experts say use caution

By Jonathan Saltzman — Boston Globe

Biotech

Vertex to pay startup Kymera $70 million in R&D deal

By Jonathan Saltzman — Boston Globe

Biotech

French drug maker Servier sets up U.S. headquarters in Boston’s Seaport

By Jonathan Saltzman — Boston Globe

Biotech

Gene therapies are a hard sell. Bluebird hopes to do better in Europe

By Adam Feuerstein

Biotech

‘It is a bit uncomfortable’: Before the criminal allegations, an awards program honored Insys and Theranos

By Rebecca Robbins

Bluebird’s gene therapy for a rare blood disease will cost $1.8 million. Cue the pricing debate

Global Blood’s sickle cell disease drug heads to the FDA, but questions about patient benefit still linger

GSK partners with CRISPR pioneer Doudna to search for new drugs

As Amazon seeks to win over health care consumers, its PillPack is accused of violating privacy

Next up for KRAS-blocking cancer drug fans: a hugely important data reveal from Mirati Therapeutics

Intermountain, Amgen subsidiary to launch DNA study of 500,000 patients

Fast-growing Vericel finds success on two fronts: knee surgery and burn care

Pharmalittle: Jacobus price for rare disease drug sets up battle with rival Catalyst; Repatha called cost-effective

Cymabay’s NASH drug ambitions dealt serious setback with negative study results

Sarepta CEO welcomes Vertex’s effort to develop a competing muscular dystrophy drug

Third Rock raises $770 million in new funding round

Haven wants to help ‘the American public get better health and reduce the costs,’ JPMorgan CEO says

Europe approves first gene therapy to treat rare blood disease

Amgen’s drug — targeting an ‘undruggable’ cancer protein — shrank tumors in half of patients

Forget controversy. AstraZeneca’s dynamic duo wants to dominate the market for cancer drugs

Troubled microbiome startup uBiome to lay off some employees, refund payments from federal insurers

Epizyme seeks early approval for drug to treat ultra-rare tumors

5 names to know at Facebook: the people behind its push into health care

Biomarin to seek approval for hemophilia gene therapy, but durability questions persist

Novartis CEO coy about pricing its gene therapy for spinal muscular atrophy

Singapore digital health startup raises $35 million, plans headquarters move to Boston

MIT-owned lab buildings in Kendall Square change hands for reported $1.1 billion

Departure of top Haven executive creates void at a crucial stage

Up and down the ladder: the latest comings and goings

As more dogs are tested for potential genetic diseases, experts say use caution

Vertex to pay startup Kymera $70 million in R&D deal

French drug maker Servier sets up U.S. headquarters in Boston’s Seaport

Gene therapies are a hard sell. Bluebird hopes to do better in Europe

‘It is a bit uncomfortable’: Before the criminal allegations, an awards program honored Insys and Theranos

Business

Sign up for our Daily Recap newsletter